Genentech

Genentech. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Herbert Boyer, it is widely regarded as the world's first dedicated biotechnology company. Its establishment marked the birth of the modern biotechnology industry, pioneering the use of recombinant DNA technology to develop medicines. Headquartered in South San Francisco, California, the company became a subsidiary of the Swiss healthcare giant Roche in 2009, following a period as a majority-owned affiliate.

History

The company's inception followed a landmark 1973 meeting between Swanson and Boyer, who co-invented recombinant DNA technology with Stanley N. Cohen. In 1978, it produced the first human protein, somatostatin, in *E. coli* bacteria, proving the commercial viability of the technology. A historic initial public offering on the New York Stock Exchange in 1980 ignited investor frenzy and symbolized the financial potential of biotechnology. The 1982 FDA approval of recombinant human insulin, developed in partnership with Eli Lilly and Company, was its first marketed product, though the 1985 approval of its own human growth hormone (Protropin) marked its first independent commercial success. The 1990 approval of Activase (alteplase) for heart attacks represented a major breakthrough in thrombolytic therapy.

Products and innovations

The company's portfolio revolutionized treatment across multiple therapeutic areas, beginning with the 1997 FDA approval of Rituxan (rituximab) for non-Hodgkin lymphoma, a pioneering monoclonal antibody cancer therapy. The 1998 approval of Herceptin (trastuzumab) for HER2-positive breast cancer introduced the paradigm of targeted, biomarker-driven oncology. In immunology, the 2003 approval of Xolair (omalizumab) for asthma was a first-in-class biologic for allergic disease. Its VEGF-inhibiting antibody Avastin (bevacizumab), approved in 2004, became a cornerstone for treating colorectal cancer, lung cancer, and other malignancies. Later innovations include the multiple sclerosis therapy Ocrevus (ocrelizumab) and the spinal muscular atrophy drug Evrysdi (risdiplam).

Research and development

Its research engine is characterized by deep expertise in antibody engineering, protein chemistry, and translational medicine. Early work focused on expressing complex proteins like tissue plasminogen activator (tPA) in CHO cells. The company's scientists developed key platforms for humanizing murine antibodies, a technology critical to the success of Rituxan and Herceptin. Its research facilities in South San Francisco, California and Pacifica, California house state-of-the-art labs for genomics, proteomics, and bioinformatics. Major collaborations have included long-term partnerships with Roche, Biogen, and academic institutions like the University of California, San Francisco. The company consistently ranks among the top organizations in U.S. patent grants.

Corporate affairs

The company operates as an independent member of the Roche Group, with Roche holding full ownership since 2009. Its corporate campus in South San Francisco, California is a landmark within the San Francisco Bay Area biotech cluster. Culturally, it has been noted for its innovative and science-driven ethos, often contrasted with traditional pharmaceutical companies. It has faced significant legal and regulatory challenges, including patent disputes over drugs like Rituxan and Herceptin, as well as FDA scrutiny of Avastin's use in breast cancer. The company maintains large-scale manufacturing operations in Vacaville, California and Oceanside, California.

Impact and legacy

The firm's founding is considered the defining event that launched the global biotechnology industry, creating a new model for drug discovery based on molecular biology. It demonstrated that startup companies could develop and commercialize groundbreaking medicines, inspiring the creation of countless biotech firms in Cambridge, Massachusetts, San Diego, and globally. Its success proved the commercial potential of recombinant DNA and monoclonal antibody technologies, attracting massive investment into life sciences. The company's drugs have treated millions of patients worldwide, fundamentally altering standards of care in oncology, immunology, and ophthalmology. Its model of seamless collaboration between research, development, and commercial teams remains highly influential.

Category:Biotechnology companies of the United States Category:Companies based in San Mateo County, California Category:Roche subsidiaries Category:Companies listed on the New York Stock Exchange